US · XBIO
Xenetic Biosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Framingham, MA 01701
- Website
- xeneticbio.com
Price · as of 2024-12-31
$2.97
Market cap 3.9M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $279.35 | +9,305.72% |
| Intrinsic Value(DCF) | $2.41 | -18.86% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.00 | $0.00 | |||
| 2014 | |||||
| 2015 | |||||
| 2016 | $453.60 | $0.00 | $0.00 | ||
| 2017 | $247.20 | $20,052.99 | $2,997,504.08 | $0.00 | $0.00 |
| 2018 | $256.80 | $91,057.26 | |||
| 2019 | $8.91 | $6.64 | $0.00 | ||
| 2020 | $25.70 | $754.89 | $0.28 | $0.00 | $0.00 |
| 2021 | $9.34 | $83.89 | $6,371.27 | $0.00 | $0.00 |
| 2022 | $3.75 | $13.80 | $2,335.10 | $0.00 | $0.00 |
| 2023 | $4.07 | $98.15 | $1,184.26 | $0.00 | $0.00 |
| 2024 | $3.77 | $279.35 | $1.17 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Xenetic Biosciences, Inc.'s (XBIO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $279.35
- Current price
- $2.97
- AI upside
- +9,305.72%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.41
-18.86% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| XBIO | Xenetic Biosciences, Inc. | $2.97 | 3.9M | +9,306% | -19% | — | — | -1.47 | 0.97 | 2.32 | 0.09 | — | 0.97 | 100.00% | -168.16% | -158.39% | -50.12% | -1285.35% | -45.24% | 0.00 | — | 7.37 | 6.89 | 1.52 | -517.00% | -156.00% | -3152.00% | -48.55% | -3.15 | -861.34% | 0.00% | 0.00% | 0.00% | 0.09 | 0.13 | -0.14 | -36.77 |
| ABP | Abpro Corporation | $0.27 | 538.98K | +18,772% | +8,137% | — | — | -0.66 | -0.31 | 26.19 | -0.85 | — | -0.30 | 100.00% | -5421.31% | -3951.91% | 14.30% | 20.14% | -180.44% | -0.21 | -25.64 | 0.19 | 0.16 | -0.08 | -3840.00% | 5000.00% | 2121.00% | -188.40% | -0.46 | 18.33% | 0.00% | 0.00% | 35.32% | -0.53 | -0.58 | 28.80 | -45.79 |
| CMND | Clearmind Medicine Inc. | $1.13 | 154.43K | — | — | — | — | -0.08 | 0.25 | — | 0.94 | — | 0.27 | 0.00% | — | — | -180.28% | 180.16% | -58.05% | 1.49 | -290.07 | 1.22 | 1.21 | 0.58 | -5494.00% | — | -189.00% | -1590.11% | -0.97 | 150.51% | 0.00% | 0.00% | 0.00% | 0.62 | 0.74 | — | -9.25 |
| ENSC | Ensysce Biosciences, Inc. | $0.62 | 1.48M | +2,572,138,798% | +223% | — | — | -1.10 | 2.36 | 1.68 | -0.83 | — | 2.36 | -38.57% | -129.17% | -153.30% | -471.83% | 16069.72% | -192.33% | 0.08 | -5.22 | 2.42 | 1.64 | 0.48 | -256.00% | 13353.00% | 6959834645.00% | -85550186.53% | -3399198.17 | 17914756446.99% | 3306.75% | -3630.90% | 3340.18% | -0.83 | 0.00 | 1.07 | -32.39 |
| KALA | KALA BIO, Inc. | $0.38 | 8.33M | — | — | — | — | -1.01 | 3.16 | — | -0.49 | — | 3.16 | 0.00% | — | — | -388.29% | 599.82% | -69.12% | 2.62 | -7.09 | 3.11 | 3.02 | 0.46 | -5977.00% | — | 369.00% | -76.03% | -1.73 | 433.08% | 0.00% | 0.00% | 11.20% | -0.49 | -0.68 | — | -17.97 |
| KZIA | Kazia Therapeutics Limite… | $8.45 | 13.69M | +90% | -63% | — | +12,468% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| QLGN | Qualigen Therapeutics, In… | $3.21 | 5.43M | +38,771% | — | — | — | -0.18 | 0.42 | — | 0.01 | -0.03 | 0.42 | 0.00% | — | — | -2210.05% | -3863.24% | -189.27% | 0.00 | -6.34 | 2.33 | 1.59 | 0.22 | 60244.00% | -10000.00% | -3859.00% | -560.87% | -3.15 | -4242.60% | 7.77% | -1.40% | 191.43% | 0.01 | 0.01 | — | -39.80 |
| SNGX | Soligenix, Inc. | $1.18 | 11.9M | — | — | — | — | -0.48 | 0.96 | — | 0.25 | — | 0.96 | 0.00% | — | — | -248.97% | 387.20% | -88.11% | 0.36 | — | 1.82 | 1.61 | 0.67 | -6066.00% | — | -233.00% | -213.60% | -1.73 | 361.77% | 0.00% | 0.00% | 35.16% | 0.25 | 0.29 | — | -38.99 |
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
- CEO
- James F. Parslow
- Employees
- 2
- Beta
- 2.31
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.41 ÷ $2.97) − 1 = -18.86% (DCF, example).